4527.T
ROHTO PHARMACEUTICAL CO.,LTD.
プライム · 医薬品 · 医薬品 · JP
JPY 3,057.00
+0.59%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 343.7B | 343.7B | 308.6B | 270.8B | 238.7B |
| Cost of Revenue | 36.1B | 151.0B | 133.7B | 113.6B | 101.2B |
| Gross Profit | 45.9B | 192.7B | 174.9B | 157.3B | 137.4B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 34.2B | 151.6B | 136.0B | 117.2B | 103.5B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 34.2B | 151.6B | 136.0B | 117.2B | 103.5B |
| Cost and Expenses | 302.6B | 302.6B | 269.7B | 230.8B | 204.7B |
| Operating Income (EBIT) | 41.1B | 41.1B | 38.9B | 40.0B | 34.0B |
| Non-Operating | |||||
| Interest Income | 237.0M | 1.1B | 1.2B | 1.5B | 962.0M |
| Interest Expense | 316.0M | 1.3B | 949.0M | 196.0M | 247.0M |
| Net Interest Income | (79.0M) | (152.0M) | 274.0M | 1.3B | 715.0M |
| Other Non-Op Income/Expense | 4.4B | 6.9B | 1.5B | 2.4B | 1.6B |
| Non-Operating Income (excl Interest) | 4.8B | 7.9B | 2.3B | 2.0B | 2.7B |
| EBT (Pre-Tax Income) | 15.1B | 46.8B | 42.3B | 41.5B | 34.3B |
| Income Tax Expense | 3.0B | 12.4B | 11.4B | 10.1B | 7.9B |
| Bottom Line | |||||
| Net Income | 34.2B | 34.2B | 31.0B | 30.9B | 26.4B |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 34.2B | 34.2B | 31.0B | 30.9B | 26.4B |
| Per Share | |||||
| Basic EPS | ¥152 | ¥152 | ¥136 | ¥136 | ¥116 |
| Diluted EPS | ¥152 | ¥152 | ¥135 | ¥135 | ¥115 |
| Revenue Per Share | ¥1,521 | ¥1,521 | ¥1,355 | ¥1,187 | ¥1,046 |
| Shares | |||||
| Basic Shares Outstanding | 226.0M | 226.0M | 227.8M | 228.1M | 228.1M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | — | 56.4B | 50.6B | 48.3B | 41.4B |
| D&A | — | 15.3B | 11.6B | 8.3B | 7.4B |
| EBIT | 41.1B | 41.1B | 38.9B | 40.0B | 34.0B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026